Copyright
©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Jul 10, 2011; 2(7): 299-302
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.299
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.299
Ref. | Age (yr)/sex | Disease | Regimen | The latency from the 1st use (d) | Outcome |
Kurakawa et al[8] | 70/M | Gastric | S-1 single | 36 | Good/recovery |
Shitara et al[9] | 37/F | Gastric | S-1 single | 150 | Poor/dead |
Tada et al[10] | 72/M | Tongue | S-1 single | 18 | Good/recovery |
Nohara et al[11] | 75/M | Colon | CDDP + S-1 | 360 | Good/recovery |
Yamamoto et al[12] | 80/M | Gastric | S-1 single | 22 | Good/recovery |
Ueyama et al[13] | 80/F | Breast | S-1 single | 5 | Good/recovery |
Present case | 66/M | Pancreas | S-1 single | 45 | Good/recovery |
- Citation: Yamane H, Kinugawa M, Umemura S, Shiote Y, Kudo K, Suwaki T, Kamei H, Takigawa N, Kiura K. An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. World J Clin Oncol 2011; 2(7): 299-302
- URL: https://www.wjgnet.com/2218-4333/full/v2/i7/299.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i7.299